Equities research analysts expect that Balchem Co. (NASDAQ:BCPC) will post earnings of $0.69 per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Balchem’s earnings, with the highest EPS estimate coming in at $0.73 and the lowest estimate coming in at $0.65. Balchem reported earnings per share of $0.76 in the same quarter last year, which would suggest a negative year over year growth rate of 9.2%. The business is scheduled to issue its next quarterly earnings results on Friday, May 3rd.

According to Zacks, analysts expect that Balchem will report full-year earnings of $3.02 per share for the current fiscal year, with EPS estimates ranging from $2.89 to $3.15. For the next year, analysts anticipate that the business will post earnings of $3.45 per share, with EPS estimates ranging from $3.30 to $3.60. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Balchem.

Balchem (NASDAQ:BCPC) last released its quarterly earnings data on Thursday, February 28th. The basic materials company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.11. Balchem had a net margin of 12.21% and a return on equity of 14.59%. The company had revenue of $163.50 million for the quarter, compared to analysts’ expectations of $161.42 million. The company’s revenue was up 2.6% on a year-over-year basis.

A number of analysts have weighed in on BCPC shares. Zacks Investment Research cut shares of Balchem from a “hold” rating to a “sell” rating in a report on Tuesday, December 11th. HC Wainwright set a $101.00 price objective on shares of Balchem and gave the stock a “buy” rating in a report on Tuesday, February 5th. BidaskClub cut shares of Balchem from a “sell” rating to a “strong sell” rating in a report on Wednesday, November 28th. Finally, Seaport Global Securities initiated coverage on shares of Balchem in a report on Thursday, February 21st. They issued a “neutral” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $105.50.

BCPC stock traded down $0.41 during midday trading on Thursday, reaching $93.09. 144,127 shares of the company were exchanged, compared to its average volume of 117,779. The company has a current ratio of 2.76, a quick ratio of 1.94 and a debt-to-equity ratio of 0.24. Balchem has a 1-year low of $73.16 and a 1-year high of $117.79. The stock has a market cap of $3.01 billion, a P/E ratio of 30.93 and a beta of 1.00.

Institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC increased its holdings in shares of Balchem by 10.7% in the 3rd quarter. Renaissance Technologies LLC now owns 201,100 shares of the basic materials company’s stock valued at $22,541,000 after acquiring an additional 19,500 shares during the period. Aperio Group LLC increased its holdings in shares of Balchem by 11.0% in the 3rd quarter. Aperio Group LLC now owns 15,776 shares of the basic materials company’s stock valued at $1,768,000 after acquiring an additional 1,566 shares during the period. Hsbc Holdings PLC acquired a new position in shares of Balchem in the 3rd quarter valued at $212,000. State of Alaska Department of Revenue increased its holdings in shares of Balchem by 2.0% in the 4th quarter. State of Alaska Department of Revenue now owns 10,784 shares of the basic materials company’s stock valued at $844,000 after acquiring an additional 210 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in Balchem by 0.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 404,678 shares of the basic materials company’s stock valued at $39,715,000 after buying an additional 2,488 shares during the period. 86.56% of the stock is currently owned by institutional investors and hedge funds.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.

Read More: Leveraged Buyout (LBO) Explained

Get a free copy of the Zacks research report on Balchem (BCPC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.